- 216 pages
- English
- ePUB (mobile friendly)
- Available on iOS & Android
eBook - ePub
Therapeutic Strategies to Overcome ALK Resistance in Cancer
About this book
Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field.
This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment.
- Explains the biology of ALK RTK, focusing on its tissue expression, structure and functionality
- Presents an overview of current treatments and the benefits of ALK TKI in lung and other cancer types, such as ALCL, neuroblastoma and inflammatory myofibroblastic tumor
- Encompasses information on systemic treatments other than TKI, including chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC
Frequently asked questions
Yes, you can cancel anytime from the Subscription tab in your account settings on the Perlego website. Your subscription will stay active until the end of your current billing period. Learn how to cancel your subscription.
No, books cannot be downloaded as external files, such as PDFs, for use outside of Perlego. However, you can download books within the Perlego app for offline reading on mobile or tablet. Learn more here.
Perlego offers two plans: Essential and Complete
- Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
- Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, we’ve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes! You can use the Perlego app on both iOS or Android devices to read anytime, anywhere — even offline. Perfect for commutes or when you’re on the go.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Yes, you can access Therapeutic Strategies to Overcome ALK Resistance in Cancer by Luc Friboulet in PDF and/or ePUB format, as well as other popular books in Biological Sciences & Biology. We have over one million books available in our catalogue for you to explore.
Information
Table of contents
- Title of Book
- Cover image
- Title page
- Table of Contents
- Series Page
- Copyright
- Cover Image Insert
- Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy”
- About the Series Editor
- Aims and Scope of Volume
- About the Volume Editor
- Preface
- Contributors
- Chapter 1 The ALK receptor tyrosine kinase journey: From physiological roles to pathological disruptions
- Chapter 2 ALK rearranged lung cancer: TKI treatment and outcome
- Chapter 3 Systemic treatments other than TKI: Reflections on chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC
- Chapter 4 Management of ALK positive patients with tumors other than lung cancer
- Chapter 5 Resistance to anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in patients with lung cancer: Single mutations, compound mutations, and other mechanisms of drug resistance
- Chapter 6 Resistance mechanisms to ALK TKIs in tumors other than lung cancer
- Chapter 7 Therapeutic strategies to overcome ALK resistance in lung cancer
- Chapter 8 Therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALK + ALCL
- Chapter 9 Drug combinations: A strategy to enhance anti-tumor activity and overcome drug resistance to ALK inhibitors in neuroblastoma
- Chapter 10 State of the art and future perspectives
- Index